The future growth of the pharmaceutical industry is good, the industry recommends to pay attention to 5 major areas

"Pharmaceutical Network Market Analysis" into October, A-share listed companies in the third quarter of the report has been disclosed.
, 115 pharmaceutical and bio-listed companies reported earnings forecasts for the first three quarters of this year.
of these, 56 were pre-increased or slightly increased, 22 were pre-reduced or slightly decreased, 14 had a first loss, 13 had continued losses, 4 had turned a loss, 1 had a continuing profit and 5 were uncertain.
the increase or decrease in net profit, more than half of pharmaceutical companies reported an increase in net profit.
this background, some pharmaceutical stocks by the fund to increase their positions.
, for example, the domestic blood sugar monitoring field leader Sanno Bio, although its share price in the third quarter of the high down, but still obtained the two public funds of Ruiyuan to increase their holdings against the trend.
Sano Bio disclosed the third quarter report shows that fund manager Fu Pengbo managed the growth value of Theo Bio 2.8168 million shares in the third quarter, Zhao Feng management of the Reyuan balanced value in the third quarter also added Sanno Bio 2.1658 million shares, the two funds held a total of 41.8261 million shares at the end of the third quarter, ranked sanno Bio's fourth and fifth largest circulating shareholders.
addition, fund manager Xie Zhiyu bucked the trend in the third quarter to increase the number of Jianyou shares, as of October 16, Jianyou shares since the third quarter of this year has fallen more than 20%.
Jianyou shares are China's leading heparin raw materials production enterprises, the company's products to heparin-based products, covering high-quality heparin raw materials, low-molecular heparin preparations and other major varieties.
third quarter of 2020 reported revenue of RMB2,158 million, up 18.08 percent year-on-year, and net profit of RMB613 million, up 36.69 percent year-on-year.
of the existence of capital markets is to improve the efficiency of asset allocation, from the recent pharmaceutical stocks frequently supported by capital action, it is not difficult to see the industry optimistic about the pharmaceutical industry in the long-term trend opportunities.
analysis that the future growth of the pharmaceutical industry is good.
On the one hand, with the promotion of consistent evaluation, volume procurement and other policies, innovative drugs have a huge room for growth, on the other hand, with the aging of the population, rising consumption levels, as well as the development of innovative medical technology, demand will drive the industry to continue to grow.
However, due to the complexity of the pharmaceutical industry and the large number of fine molecular industries, the industry believes that the track should be preferred, focusing on five areas: innovative pharmaceuticals and biopharmaceuticals, innovative devices, vaccines and blood products-related services, research and development outsourcing services and API supply chain, as well as specialized medical services.
In terms of innovative drugs and biopharmaceuticals, China's independent new drugs have begun to accelerate the growth of long-term, head enterprises often have more innovative drugs, such as Hengrui Pharmaceuticals, China Biopharmaceuticals, Dongsun, Shi Pharmaceutical Group and Fosun Pharmaceuticals, these pharmaceutical companies have more than 10 innovative drugs, of which Hengrui Pharmaceuticals has 31 innovative drugs are included in the index;
believe that in the future, the competition of pharmaceutical manufacturers is the competition for innovative drugs, and the possession of good varieties is likely to win the competition.
innovative devices, the device market has entered a supply-driven phase as new demand and technology have expanded.
At the same time, import substitution and increased concentration will lead to accelerated concentration of industry head enterprises, in the future with more support for good policies, innovative devices into the golden development opportunities, medical devices as an important support for new medical technology and medical services will usher in opportunities.
can be seen that the cyclical attributes and drivers vary between these sub-sectors.
e.g. chemicals, API is a cyclical industry, related to the fixed asset investment cycle, but demand is rigid, there is strict access, vaccines, Traditional Chinese medicine, etc. have consumption attributes, brand power is very important, pharmaceutical service research and development and outsourcing is a very typical service-oriented industry, affected by the industry climate, but will be relatively lagging behind.
pharmaceutical industry covers the three major macroeconomic business models and the definition of the life cycle of enterprises, the industry believes that the pharmaceutical industry investment has great opportunities, there are many opportunities to create excess returns.